Publicacións nas que colabora con Julen Oyarzabal Santamarina (10)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2021

  1. Searching for peptide inhibitors of t regulatory cell activity by targeting specific domains of foxp3 transcription factor

    Biomedicines, Vol. 9, Núm. 2, pp. 1-20

2020

  1. Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression

    Journal of Urology

2019

  1. Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Nature Medicine

2018

  1. Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in b lymphoid neoplasms

    Haematologica, Vol. 103, Núm. 6, pp. 1065-1072

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724

  2. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8

  3. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

    PLoS ONE, Vol. 12, Núm. 9

2015

  1. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189